Dalpiciclib vs Tibremciclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Dalpiciclib

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04993430 (registry estimate)

No aligned efficacy figure on record for this race.

Tibremciclib · Kangmeina

Marketed by Betta Pharmaceuticals Co.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05433480 · Phase 3 · status unknown

This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.

Result from the peer-reviewed publication (JAMA Oncology 2025); the registry has no posted results and its status is not updated.

Reported efficacy

Investigator-assessed PFS (up to 3 years): Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 (met)

Result source: NCT05433480

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDalpiciclibTibremciclib
PFS, median—Trial running · NCT06612814—Not reported
OS, median—Trial running · NCT06612814—Not reported
ORR—Trial running · NCT06612814—Not reported
Clinical benefit rate—Trial running · NCT06612814—Not reported

PFS, median

Dalpiciclib
—Trial running · NCT06612814
Tibremciclib
—Not reported

OS, median

Dalpiciclib
—Trial running · NCT06612814
Tibremciclib
—Not reported

ORR

Dalpiciclib
—Trial running · NCT06612814
Tibremciclib
—Not reported

Clinical benefit rate

Dalpiciclib
—Trial running · NCT06612814
Tibremciclib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Dalpiciclib: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tibremciclib
Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 NCT05433480 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalpiciclib's landscape · Tibremciclib's landscape